Evidence map›Paper›PMID 29070077›Full record

SynthesisDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2017

Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials.

Khosro Keshavarz, Farhad Lotfi, Ehsan Sanati, Mahmood Salesi, Amir Hashemi-Meshkini, Mojtaba Jafari, Mohammad M Mojahedian, Behzad Najafi, Shekoufeh Nikfar

Abstract readComparative StudyNetwork Meta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Khosro KeshavarzHealth Human Resources Research Center, Department of Health Economics, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, IR, Iran.
Farhad LotfiHealth Human Resources Research Center, Department of Health Economics, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, IR, Iran.
Ehsan SanatiDepartment of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR, Iran.
Mahmood SalesiAtherosclerosis Research center, Baqiyatallah University of Medical Sciences, Tehran, IR, Iran.
Amir Hashemi-MeshkiniDepartment of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR, Iran.
Mojtaba JafariHealth Human Resources Research Center, Department of Health Economics, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, IR, Iran.
Mohammad M MojahedianDepartment of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR, Iran.
Behzad NajafiIranian center of Excellence in health management, Department of health services management, School of management and medical informatics, Tabriz University of medical sciences, Tabriz, Iran.
Shekoufeh NikfarDepartment of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy and Evidence-Based Medicine Group, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran. shekoufeh.nikfar@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes is one of the most common chronic and costly diseases worldwide and type 2 diabetes is the most common type which accounts for about 90% of cases with diabetes. New medication-therapy regimens such as those containing linagliptin alone or in combination with other medications (within the category of DDP-4 inhibitors) must be evaluated in terms of efficacy and compared with other currently used drugs and then enter the medication list of the country. Hence, this study aimed to compare the clinical efficacy of the two drugs, i.e. linagliptin and sitagliptin, in patients with type 2 diabetes.

methodsA systematic review was conducted to identify all clinical trials published by 2015 which compared the two drugs in patients with type 2 diabetes. Using keywords such as "linagliptin", "type 2 diabetes mellitus", "sitagliptin" and related combinations, we searched databases including Scopus, PubMed, and Web of Science. The quality of the selected studies was evaluated using the Jadad score. Considering primary and secondary outcomes extracted from the reviewed studies, a network meta-analysis was used to conduct a systematic comparison between the two studied drugs.

resultsThis network meta-analysis included 32 studies (Linagliptin vs PLB: n = 8, Sitagliptin vs PLB: n = 13, Linagliptin + MET vs PLB + MET: n = 4, and Sitagliptin + MET vs PLB + MET: n = 7) and a total of 13,747 patients. The results showed no significant difference between linagliptin and sitagliptin in terms of key efficacy and safety outcomes such as HbA1c changes from baseline, body weight change from baseline, percentage of patients achieving HbA1c <7, and percentage of patients experiencing hypoglycemic events (p > 0.05). The results showed that the efficacy of the two drug regimens was the same.

conclusionsBased on the results, there was no significant difference between the two drugs, i.e. linagliptin and sitagliptin, in terms of efficacy; in other words, the efficacy of the two drugs was the same. Therefore, the use of these two drugs depends on their availability and cost. Graphical abstract of the network meta-analysis performed to evaluate the alternatives under the study.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsLinagliptinSitagliptin PhosphateAgedAged, 80 and overBody WeightFemaleGlycated HemoglobinHumansMaleMiddle AgedTreatment OutcomeGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsLinagliptinSitagliptin PhosphateLinagliptinNetwork meta-analysisSitagliptinType 2 diabetes mellitus

Identifiers

PMID29070077
PMCPMC5655990

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.